Objectives: To assess the feasibility [defined as successful circumferential staining of the sciatic nerve (SN) over > 2 cm] and incidence of needle-nerve contact of a novel ultrasound-guided out-of-plane approach targeting the subepimysial perineural compartment cranial to the SN, compared with the conventional caudocranial in-plane technique.
Study design: Prospective, randomized, experimental anatomical study.
Animals: Twelve canine cadavers (24 pelvic limbs).
Methods: Bilateral injections of 0.1 mL kg-1 of a lidocaine-dye mixture were performed at the midthigh level in each canine cadaver, with one limb randomly assigned to the in-plane (caudocranial) approach and the contralateral limb to the out-of-plane (lateromedial) approach. Ultrasound recordings were analyzed for needle-nerve contact and number of attempts to reach the injection site. Anatomical dissections assessed the length of circumferential staining. The incidence of needle-nerve contact between approaches was analyzed using McNemar's test, with statistical significance set at p < 0.05. Data not submitted to statistical testing are presented as median and 25th and 75th percentiles (Q1-Q3).
Results: Needle-nerve contact occurred in 9/12 (75%) in-plane injections but in 0/12 (0%) out-of-plane injections (p = 0.003). The out-of-plane approach required fewer attempts to reach the injection site [1 (1-2)] than the in-plane approach [2.5 (2-3.5)] and a shorter needle insertion depth [2.4 (2.1-3.1)] versus 4.61 (3.6-5.2) cm]. Circumferential staining was achieved in all specimens, with staining lengths of 3.5 (2.8-6.6) cm for the in-plane and 4.3 (3.5-4.9) cm for the out-of-plane approach.
Conclusions and clinical relevance: The ultrasound-guided out-of-plane approach targeting the subepimysial perineural compartment cranial to the SN in dogs consistently achieved circumferential staining without observable needle contact, requiring fewer attempts and a shorter needle path compared with the traditional in-plane technique.
Objective: To compare the length of nerve staining of two volumes of bupivacaine-dye solution following ultrasound-guided injections of sciatic and femoral nerves using a lateral approach in chicken cadavers.
Study design: Prospective, randomized, blinded, crossover design.
Animals: A group of eight Ross 708 breeder hen cadavers weighing 1.7 ± 0.5 kg.
Methods: Chicken cadavers were placed in lateral recumbency, and an ultrasound transducer was positioned perpendicular to the femur, on the proximolateral aspect of the thigh, allowing visualization of the sciatic nerve and femoral neurovascular sheath in the same acoustic window. Each chicken leg (n = 16) was assigned to one of two treatments: low-volume (0.2 mL per nerve; LV) or high-volume (0.8 mL per nerve; HV) bupivacaine-dye solution. Perineural injections in the sciatic and femoral nerves were performed by advancing an insulated needle in-plane in a caudal-to-cranial direction. The coelomic cavities were inspected for dye solution. Gross dissections were conducted to assess distribution of the dye in both phases. Length of nerve staining between LV and HV groups was compared using a two-tailed t test.
Results: All sciatic nerves for both groups were stained. One femoral nerve in the LV group and two in the HV group were not stained. The mean ± standard deviation length of nerve staining for LV and HV was 2.3 ± 0.7 and 4.7 ± 1.0 cm (p = 0.001) for the sciatic nerve, and 1.5 ± 0.5 and 2.8 ± 0.7 cm (p = 0.002) for the femoral nerve, respectively. Dye was detected in the coelomic musculature of one chicken and coelomic cavity of another after femoral nerve injections.
Conclusions and clinical relevance: Both low- and high-injection volumes effectively stained all sciatic and most femoral nerves using an ultrasound-guided lateral approach. However, coelomic cavity injection may occur with this approach to the femoral nerve.
Objective: To determine the incidence of intra-anesthetic hyperglycemia and identify associated risk factors in nondiabetic dogs undergoing general anesthesia.
Study design: Retrospective, single-center cohort study.
Animals: A total of 400 client-owned, nondiabetic dogs anesthetized for surgical or diagnostic procedures between May and December 2024.
Methods: Medical records were reviewed to collect data on patient characteristics, anesthetic management and intra-anesthetic blood glucose concentrations measured via arterial blood gas analysis. Hyperglycemia was defined as blood glucose > 180 mg dL-1 (10 mmol L-1) and severe hyperglycemia as > 300 mg dL-1 (16.7 mmol L-1). Univariable and multivariable logistic regression analyses were performed to identify independent associated factors of hyperglycemia.
Results: Intra-anesthetic hyperglycemia occurred in 14.8% (59/400) of dogs, and severe hyperglycemia was observed in 4.3% (17/400). Multivariable logistic regression identified the following independent risk factors for hyperglycemia: preanesthetic fasting glucose ≥ 100 mg dL-1 (5.6 mmol L-1) [odds ratio (OR) 4.40, 95% confidence interval (CI): 1.98-9.79, p < 0.001], American Society of Anesthesiologists physical status classification (ASA status) ≥ 3 (OR 2.78, 95% CI: 1.18-6.54, p = 0.019), medetomidine use (OR 4.62, 95% CI: 1.03-20.75, p = 0.046), undergoing surgery (OR 3.09, 95% CI: 1.21-7.85, p = 0.018), intra-anesthetic hypothermia < 36 °C (OR 3.09, 95% CI: 1.29-7.38, p = 0.011), dopamine (OR 22.75, 95% CI: 9.36-55.33, p < 0.001) and norepinephrine use (OR 4.63, 95% CI: 1.76-12.20, p = 0.002), with dopamine showing the strongest association.
Conclusions and clinical relevance: Intra-anesthetic hyperglycemia occurred in nondiabetic dogs, with specific risk factors identified: elevated preanesthetic fasting glucose, ASA status ≥ 3, medetomidine use, surgery, intra-anesthetic hypothermia, dopamine and norepinephrine use. Patients with these risk factors may be predisposed to hyperglycemia, highlighting the importance of intra-anesthetic glucose monitoring.

